← BioTransfer GEO Dataset Finder
GEO series

Autologous multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma: results of a Phase I, three-arm, nonrandomized clinical trial (TACTOPS)

GSE307914 Homo sapiens (human) RNA-seq (gene expression) 24 samples Submitted 2025/09/12 Platform GPL34281
At a glance

RNA-seq (gene expression) · human · 24 samples

What it is
RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism
Homo sapiens (human)
Topic
Pancreatic cancerThis series is part of our curated briefing on it.
Samples
24 samples: 24 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
Data you can get
A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trialNature medicine · 2026
Summary (written by the submitters)
T-cell therapy has thus far proven ineffective for treating pancreatic ductal adenocarcinoma (PDAC), in part due to heterogeneous expression of tumor-associated antigens (TAAs). In a Phase I/II trial, autologous ex vivo expanded T-cells targeting five TAAs - PRAME, SSX2, MAGEA4, Survivin, and NY-ESO-1 - were prepared and administered (1x107 cells/m2/infusion) monthly to subjects with advanced PDAC responding (Arm A, n=13) or refractory to (Arm B, n=12) first-line chemotherapy, or to those with potentially resectable disease (Arm C, n=12).
Read the full summary ↓
Primary endpoints were safety and feasibility of delivering 6 infusions; additional endpoints were clinical and immunologic response. Of 56 subjects procured, 37 were infused (median 3 doses), with only one treatment-related serious adverse event reported. Disease control rates in Arms A and B were 84.6% (95% CI: 54.6%-98.1%) and 25% (95% CI: 5.5%-57.2%), respectively; in Arm C, 2/9 resected subjects remain disease-free at 55 and 66 months. The infused cells persisted for up to 12 months post-infusion, and elevated levels of effector, tumor-directed T cells were detected both during dosing (p=0.027) and follow-up in “responders” (objective response in Arms A/B, no relapse in Arm C) compared to “non-responders” (progression in Arms A/B, relapse in Arm C).
Published in
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial
Musher BL, Vasileiou S, Smaglo BG et al. · Nature medicine 2026 · PMID 41482561 · doi:10.1038/s41591-025-04043-5
This dataset
Open GSE307914 in finder → Find more human RNA-seq datasets → Pancreatic cancer landscape →
Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓
2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE307914_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓
3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1327797 and SRA study SRP619665. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 41482561) ↗
Study design
24 samples, each with a distinct title — no replicated groups

Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.

How we read this: Read from 24 sample titles: 24 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study
More Pancreatic cancer datasets

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.